Paediatric Haematology and Oncology, Department of Paediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
Br J Haematol. 2012 Sep;158(6):772-7. doi: 10.1111/j.1365-2141.2012.09221.x. Epub 2012 Jul 23.
The prognostic relevance of CRLF2 -rearrangements in childhood acute B-cell precursor lymphoblastic leukaemia (ALL), was assessed by a comparative analysis of 114 non-Down-syndrome patients (99 P2RY8-CRLF2+ , 15 IGH@-CRLF2+ ), 76 from the AIEOP-BFM ALL 2000 and 38 from the MRC ALL97 trials. The 6-year cumulative relapse incidence of P2RY8-CRLF2+ patients treated on the two trials was not statistically different: 0·37 ± 0·06 vs. 0·25 ± 0·08 (P = 0·194). In contrast, 0/9 IGH@-CRLF2+ AIEOP-BFM, but 5/6 ALL97 patients relapsed. Conclusively, P2RY8-CRLF2+ patients had an intermediate protocol-independent outcome while the different prognosis of IGH@-CRLF2+ patients could be related to the different structures of the applied treatment protocols.
通过对 114 例非唐氏综合征患儿(99 例 P2RY8-CRLF2+,15 例 IGH@-CRLF2+)的比较分析,评估了 CRLF2 重排对儿童急性 B 细胞前体淋巴母细胞白血病(ALL)的预后意义。这 76 例患儿来自 AIEOP-BFM ALL 2000 试验,38 例来自 MRC ALL97 试验。在这两项试验中,接受治疗的 P2RY8-CRLF2+患者 6 年累积复发率无统计学差异:0.37±0.06 对 0.25±0.08(P=0.194)。相比之下,AIEOP-BFM 试验中没有 IGH@-CRLF2+患者复发,但 ALL97 试验中有 5/6 例复发。因此,P2RY8-CRLF2+患者具有中间的方案独立预后,而 IGH@-CRLF2+患者的不同预后可能与所应用治疗方案的不同结构有关。